ASCO 2024: Focus on Lung Cancer
Advertisement
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
A panel of experts shares their insights on key developments and advances in lung cancer treatment research.
Experts discuss important management considerations and the importance of working with a multidisciplinary team.
The panel discusses key questions about NSCLC treatment regimens and the research that could answer them.
Experts weigh in on the long-term results presented at the 2024 American Society of Clinical Oncology Annual Meeting.
The panel discusses combination therapies and treatment considerations for patients without targetable mutations.
Experts weigh in on unmet needs and what clinicians should consider when treating patients who lack driver mutations.
An expert panel discusses treatment and quality-of-life considerations, as well as what to do while awaiting NGS results.
Experts weigh in on NSCLC screening and diagnostic challenges and the prevalence of metastatic disease at diagnosis.
Researchers say the results support the evaluation of the treatment in the phase 3 CodeBreaK 202 trial.
Study investigators say that extended follow-up research on nivolumab consolidation is essential.
Dr. Paz-Ares shares his insights on the study's results and the remaining questions about ADCs in lung cancer treatment.
The CheckMate 9LA study evaluated first-line nivolumab plus ipilimumab with 2 cycles of platinum-doublet chemotherapy.
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Most patients who received adjuvant osimertinib achieved MRD negativity.
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
Dr. Spigel speaks about how the American Society of Clinical Oncology Annual Meeting inspires collaboration and discovery.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.